00:00It's the most important elements for us when we provide medication and innovation to the patients.
00:07And when you talk about Jiao Ping Huan, Jiao Ping Huan is a very broad category.
00:11What I can speak to is really about the metatide that we are coming from Novonorsk.
00:18Now, Jiao Ping Huan, I think what you also mentioned, Jiao Ping Huan,
00:20there's a lot of people sort of doing self-medication and perhaps coming from,
00:25not exactly from the prescription from the doctors.
00:27And that's something that we strongly advise against.
00:31Because CLP1 or Simagotide is a prescription drug.
00:35And for any patient initiating such treatment, it requires proper HCT or doctor's initiation
00:44and also doctor's follow-up as well.
00:47So that's a very important element.
00:49Now, to your question about safety, and I can speak to Simagotide myself.
00:53So Simagotide is a molecule which we have launched in the market for the last probably more than 10 years.
01:02And Simagotide has been studied in a huge number of clinical trials.
01:11So we all know that when you bring the product to the market, especially pharmaceutical products,
01:15you need to have a very strong base of clinical trial.
01:18Around the 54,000 patients have been through the clinical trial.
01:23So the molecule itself has been extensively studied.
01:26Now, when we talk about the usage of the molecule around the world,
01:29and the molecule has been utilized by around the 49 million patient years.
01:36So you will say, what is the patient years, right?
01:38So patient years is really the basic concept to say if you are having one patient
01:43on the treatment molecule for one year, and that's one patient year.
01:47Now for the Simagotide molecule itself, we have around 49 million patient years.
01:52So with that sort of safety record behind us, we can very simply say that Simagotide is a safe treatment
01:59for patients with obesity and diabetes.
02:06Any other questions?
02:10And proper diet and proper exercise is still super important for patients.
02:15And medication alone cannot solve the problem.
02:17So it's also very important for me to mention that because diet and exercise represent a lifestyle change.
02:23And ultimately, obesity is a chronic disease and requires lifestyle change in order to proper treat it.
02:31Now if you talk about treatment, then what I can speak to is the treatment that we provide.
02:36So what we have is Simagotide-Sol-K1 treatment.
02:40That's currently available in the market.
02:42And that's provided the innovation in the medication to the patient.
02:48The T-L-K1 class itself, yes, that's also the class for the obesity treatment as well.
02:54And there are a couple of options, but for us, the Simagotide is one of the options.
03:00There's a couple of options.
03:02No, Simagotide itself has a brand name of Vigobin for treatment for obesity treatment.
03:10It's a prescription drug.
03:12Therefore, it's important for me to emphasize that for any patient who requires treatment,
03:17they will need to consult with the doctors first.
03:21Beyond the scale, an initiative guided by our shared vision of caring for the communities we serve across the Visayas
03:29and Midanao.
03:30Obesity and diabetes continue to rise in our regions, affecting not just individual health, but families and communities as a
03:39whole.
03:41The Gankayo silently struggling, and for many, access to timely screening and modern care remains a challenge.
03:49These conditions are often managed quietly, hilong-hilong lang, and then we do a lot of self-medication.
03:57Pero, ginaagwanta lang nila adlaw-adlaw, not knowing where to go, who to talk to, and maybe afraid sa post.
04:04Or there are really old mga kapaw na kagmatinuuan na ito on how to lose weight, what's bad, what's good.
04:13Yes, we firmly believe that Visayas and Midanao deserve more accessible options for health.
04:24So, that is where Rose Pharmacy will be the partner of Novo Nordisk, as our store network will be able
04:36to spread our advocacy,
04:39not just in the big cities, but also in the smaller towns and municipalities.
04:43Peace.
05:14Peace.
05:15Peace.
05:15Peace.
05:16Peace.
05:17Peace.
05:20Peace.
05:20Peace.
05:20Peace.
Comments